Platform Usage to Support Advanced Drug Modalities

Technology platforms not typically used for regulated bioanalysis are now utilized more frequently to support cell and gene therapy programs. Flow cytometry, ELISpot and quantitative PCR are all tools now leveraged to assess exposure, durability, immunogenicity and function of novel modalities. In this webinar, we’ll discuss their utilization and current thoughts around expectations for performance characteristics in the regulated space.